Clinical Trial Update: A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Phase 1/2 study assessing Sacituzumab Tirumotecan plus Enfortumab Vedotin with or without Pembrolizumab in advanced urothelial carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• Pembrolizumab (pembrolizumab)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING